Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
MOMA Therapeutics
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06974110CT.gov Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lynch Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Moma-341 (this asset) | MOMA Therapeutics | P1 | CC · 43 |
| Aspirin | M.D. Anderson Cancer Center | P3 | BB |
| Naproxen | M.D. Anderson Cancer Center | P2 | B |
| Acetylsalicylic Acid Lysinate | Assistance Publique - Hôpitaux de Paris | P3 | B |
| Fluorouracilum | National Cancer Institute (NCI) | P3 | B |
| Secretin | Johns Hopkins University | P3 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Atezolizumab | National Cancer Institute (NCI) | P3 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P3 | B |
+17 more in the Lynch Syndrome cohort
Other indications for Moma-341
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Endometrial Carcinoma | — | P1 | C · 37 |
| Gastric Cancer | — | P1 | C · 37 |
| Cancer | — | P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Moma-341 in Lynch Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/moma-341-lynch-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →